Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY Group's EBIT per Share for the
six
months ended in Dec. 2025 was HK$0.09.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.23.
During the past 12 months, the average EBIT per Share Growth Rate of SSY Group was -56.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -25.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 0.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 5.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for SSY Group's EBIT per Share or its related term are showing as below:
HKSE:02005'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25.1 Med: 11.9 Max: 36.6
Current: -25.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of SSY Group was 36.60% per year. The lowest was -25.10% per year. And the median was 11.90% per year.
HKSE:02005's 3-Year EBIT Growth Rate is ranked worse than 87.42% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs HKSE:02005: -25.10
SSY Group's EBIT for the
six
months ended in Dec. 2025 was HK$265 Mil.
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
SSY Group EBIT per Share Related Terms
SSY Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for SSY Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.23
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (HKSE:02005) has a EBIT per Share of HK$0.23 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on SSY Group and its competitors. According to the industry distribution chart, SSY Group ranks #709 out of 811 companies in the Drug Manufacturers industry, placing it in the top 87.4%.
Is SSY Group's EBIT per Share too high?
SSY Group's current EBIT per Share is HK$0.23. Based on the distribution chart, SSY Group ranks #709 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SSY Group has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SSY Group's EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #709 out of 811 companies for EBIT per Share. This places SSY Group in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current EBIT per Share is HK$0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
Based on GuruFocus' analysis, SSY Group (HKSE:02005) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.07, compared to a current price of HK$2.44 — trading 20.5% below its estimated fair value. The current EBIT per Share is HK$0.23. SSY Group's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For SSY Group (HKSE:02005), the current EBIT per Share is HK$0.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (HKSE:02005) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of HK$2.44 is trading 20.5% below its estimated GF Value™ of HK$3.07.
GuruFocus considers SSY Group to be Modestly Undervalued.
Key valuation signals for HKSE:02005:
EBIT per Share: HK$0.23
GF Value™: HK$3.07 vs. price of HK$2.44 (20.5% below fair value)
No single metric tells the full story. See the HKSE:02005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
87GF Score
Get the complete analysis for HKSE:02005
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02005 has been successfully added to your 
